[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-failure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,44,83,110,140,180,209,228,263,290,315,341,365,393,419,445,482,506],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645232","analysis-of-continuous-kidney-replacement-therapy-ckrt-treatments-with-multiflux-hemofilters-using-regional-citrate-anticoagulation-rca-or-systemic-heparin-anticoagulation-100645232",false,"NCT07679568","Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation","Analysis of CKRT Treatments With multiFlux Hemofilters Using RCA or Systemic Heparin Anticoagulation","RCA-Flux","Inclusion Criteria:\n\nGeneral:\n\nPatients ≥ 18 years:\n\n* Informed consent signed and dated by the investigator; and\n\n  1. if patient is able to give consent: by the study patient\n  2. if patients unable to give consent: by the legal representative\u002Fspouse according to § 1358 BGB or\n  3. if an emergency situation is determined: by an independent consultant physician.\n\n     Pediatric Patients \\\u003C 18 years:\n* Informed consent signed and dated by legal representative and investigator\u002F authorized physician.\n* The minors have received the information referred to in Article 63(2) Medical Device Regulation (MDR) in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children. If able, the minors have to sign the informed consent, too.\n* The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator\n\nStudy specific:\n\n* Body weight ≥ 8kg\n* Acute Kidney Injury (AKI) with clinical indication for CKRT\n* Clinically estimated life expectancy greater than 3 days\n\nExclusion Criteria:\n\n* Any conditions which could interfere with the patient's ability to comply with the study\n* Patient or legal representative or authorized physician during emergency situation is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations\n* Participation in a different interventional clinical study during the preceding 30 days\n* Previous participation in the same study\n* Uncontrolled bleeding and coagulation disorders","ALL","1 Year",{"count":20,"type":21},62,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to assess the performance of the multiFlux hemofilterwith regional or systemic anticoagulation during CKRT treatments. The multiFlux hemofilter is a single use device within the extracorporeal blood circuit during extracorporeal blood purification treatments for acute renal replacement therapies.",[25,26],"Acute Kidney Injury","Renal Failure",[28,29,30],"Continuous kidney replacement therapy","Regional citrate anticoagulation","Systemic heparin anticoagulation","NOT_YET_RECRUITING","2026-06-25",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":21},"2026-07",{"date":39,"type":21},"2027-12",{"name":41,"class":42},"Fresenius Medical Care Deutschland GmbH","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":43},"100639360","comparison-of-citrate-and-heparin-anticoagulation-during-postdilution-hemodiafiltration-100639360","NCT07618858","Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration","Efficiency and Biocompatibility of Postdilution Hemodiafiltration Using Different Anticoagulation Methods: A Randomized Crossover Clinical Trial","CITRA-HDF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End-stage kidney disease requiring maintenance postdilution hemodiafiltration\n* Stable chronic hemodialysis treatment three times weekly\n* Functional arteriovenous fistula\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation therapy\n* Dual antiplatelet therapy\n* Significant coagulopathy\n* Active bleeding\n* Acute kidney injury","18 Years",{"count":54,"type":21},20,"INTERVENTIONAL",[57],"NA","This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.\n\nThe primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).\n\nSecondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.\n\nTwenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.\n\nThe study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.",[60,61,62,26],"End-Stage Kidney Disease","Hemodiafiltration","Chronic Hemodialysis",[64,65,61,66,67,68,69,29,70,71,72],"Citrate anticoagulation","Heparin anticoagulation","Dialysis","Biocompatibility","Beta-2 microglobulin","Complement activation","Chronic dialysis","Thrombin-antithrombin complex","Platelet factor 4","2026-05-27",{"date":75,"type":35},"2026-06-01",{"date":77,"type":21},"2026-06-05",{"date":79,"type":21},"2027-04-01",{"name":81,"class":82},"University Medical Centre Ljubljana","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":55,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100546104","clinical-performance-of-the-therapy-option-flexpoint-of-the-pd-cycler-sleepsafe-harmony-100546104","NCT06390592","Clinical Performance of the Therapy Option FlexPoint of the PD Cycler Sleep•Safe Harmony","Clinical Performance of the Therapy Option FlexPoint (Flexible Volume and Dwell Time Management) of the PD Cycler Sleep•Safe Harmony","FlexPoint","Inclusion Criteria:\n\n* Informed consent signed and dated by study patient and investigator\u002F authorised physician\n* Minimum age of 18 years\n* CKD patients with indication for renal replacement therapy\n* Patients being treated with APD for at least 3 months\n* Patients using the sleep•safe harmony PD cycler (version 3.1)\n* Fluid status regularly monitored with Body Composition Monitor (BCM)\n* Proper functioning catheter\n* Intraperitoneal Pressure (IPP) ≤ 18 cm H2O\n* Ability to understand the nature and requirements of the study\n\nExclusion Criteria:\n\n* Any conditions which could interference with the patient's ability to comply with the study\n* Previous participation in the same study\n* Patients who have any condition prohibiting the use of BCM, like patients with major amputations (e.g. lower leg)\n* Patients receiving polyglucose containing PD solution\n* Respiratory or abdominal wall disease deemed to contraindicate intraperitoneal fill volume (FV) manipulation\n* Patients who suffer from peritonitis\u002Fexit site infection during the last 4 weeks\n* Women of childbearing age without effective means of contraception, pregnancy (pregnancy test will be conducted at start and end of study) or lactation period\n* Life expectancy \\\u003C3 months\n* Participation in an interventional clinical study during the preceding 90 days",{"count":92,"type":21},24,[57],"Analysis and comparison of treatments with and without the FlexPoint technology (flexible volume and dwell time management) of the PD cycler sleep•safe harmony",[26,96],"Chronic Kidney Disease",[98,99,100,101],"Renal replacement therapy","Peritoneal dialysis","Automated peritoneal dialysis","PD cycler","2026-04-08",{"date":104,"type":35},"2026-04-13",{"date":106,"type":21},"2026-06",{"date":108,"type":21},"2027-05",{"name":41,"class":42},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":55,"phases":120,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":43},"100527025","early-phase-1-pilot-study-dara-cybord-in-newly-diagnosed-multiple-myeloma-patients-with-renal-failure-100527025","NCT06142396","Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","Inclusion Criteria:\n\n1. Patients must have had a confirmed new diagnosis of MM following revised IMWG criteria.\n2. Patients must have Zubrod\u002FECOG Performance Status ≤ 2.\n3. Patients must have renal insufficiency. Renal insufficiency is defined as eCrCl \\\u003C 60 mL\u002Fmin (using Cockcroft-Gault Equation for Cr Cl) and\u002For necessitating dialysis\n4. must not have known allergies to any of the study drugs. Must have adequate organ function.\n5. International normalized ratio (INR) and prothrombin time (PT) ≤1.5 × ULN. Activated partial thromboplastin time (aPTT) ≤1.5 × ULN.\n\nExclusion Criteria:\n\n* 1\\. Known seropositive for: human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C.\n\n  2\\. Known Chronic obstructive pulmonary disease (COPD). 3. Known Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.\n\n  4\\. Known Clinically significant heart disease is defined as: myocardial infarction within 6 months before enrollment, or unstable or uncontrolled disease\u002Fcondition related to or affection cardiac function.\n\n  5\\. Women who are pregnant, breastfeeding, or planning to become pregnant while enrolled in this study.\n\n  6\\. Patients with grade 3 or 4 peripheral neuropathy 7. Patients with other active malignancies that require concurrent treatment 8. Known CNS involvement or plasma cell leukemia, or AL amyloidosis 9. Participants with active infection requiring systemic therapy 10. Has known substance abuse disorders that would interfere with cooperation with the requirements of the study.","80 Years",{"count":119,"type":21},30,[121],"EARLY_PHASE1","The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients.\n\nThe primary questions this study aims to answer are:\n\n1. To evaluate the very good partial response rate (VGPR) after 4 cycles of Dara-CyBord.\n2. To evaluate the renal response rate (RRR) after 4 cycles of Dara-CyBord.",[124,26],"Multiple Myeloma",[126,127,128,129],"Daratumumab","Bortezomib","Cyclophosphamide","Dexamethasone","RECRUITING","2026-03-11",{"date":133,"type":35},"2026-03-12",{"date":135,"type":35},"2024-11-01",{"date":137,"type":21},"2027-11-01",{"name":139,"class":82},"Augusta University",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":55,"phases":149,"briefSummary":150,"conditions":151,"keywords":161,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100516231","save-fistulas-the-selfwrap-assisted-arteriovenous-fistulas-study-100516231","NCT06001827","SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study","SAVE-FistulaS","Inclusion Criteria:\n\n* Age of at least 18 years\n* Referred for creation of a new AVF\n* Willing and able to comply with study requirements, communicate with the study team, and attend follow up visits over a period of 36 months\n\nExclusion Criteria:\n\n* Planned index procedure to revise or repair an existing fistula\n* Target artery inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Target vein inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound\n* Known central venous stenosis of at least 50% on the side of surgery\n* Presence of a stent or a stent graft within the access circuit\n* Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation\n* Known or suspected active infection at the time of surgery\n* Congestive heart failure NYHA class 4\n* Prior steal on the side of surgery;\n* Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study\n* Life expectancy less than 12 months\n* Expected to undergo kidney transplant surgery within 6 months of enrollment\n* Expected to undergo home hemodialysis\n* Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening\n* Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study\n* Unwillingness or inability to give consent and\u002For comply with the study follow up schedule\n* Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study.",{"count":148,"type":21},600,[57],"This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.",[152,153,154,155,156,157,26,158,159,160],"Chronic Kidney Diseases","End Stage Renal Disease","Arteriovenous Fistula","Hemodialysis Access Failure","ESRD","Vascular Access Complication","Catheter Complications","Catheter Dysfunction","Renal Insufficiency",[162,163,164,165,166,167,168,66,96,153,154,169],"Vascular Surgery","Vascular Access","Nephrology","Bioabsorbable","Perivascular Wrap","External Support","Hemodialysis","AVF","2026-02-12",{"date":172,"type":35},"2026-02-17",{"date":174,"type":35},"2024-01-03",{"date":176,"type":21},"2029-12",{"name":178,"class":42},"VenoStent",28,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":55,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":43},"100615540","post-filter-hematocrit-100615540","NCT07293936","Post-Filter Hematocrit","Validation of a Post-Filter Hematocrit Calculation Formula: A Comparative Analysis With Measured Post-Filter Hematocrit Values","CRRTHCT","Inclusion Criteria:\n\n* patients initiated on CRRT age equal than or greater to 18 years of age\n\nExclusion Criteria:\n\n* patients on ECMO",{"count":54,"type":21},[57],"Filter clotting is a major complication of continuous renal replacement therapy (CRRT), resulting in blood loss, reduced treatment efficacy, and increased cost. One modifiable factor associated with filter clotting is filtration fraction (FF), or the proportion of plasma water being removed from the blood over the course of the filter. In convention, a cutoff of FF\\\u003C20-30% has been used to prevent hemofilter clotting, but no evidence correlating FF with hemofilter clotting has been documented. Some experts have proposed that post-filter hematocrit (Hct) could be a more direct marker for determining hemofilter clotting risk, but evidence supporting clinical utility of this marker is lacking.\n\nHCTpost=HCTpre\u002F(FF(HCTpre-1)+1)\n\nIn our proposed validation study, we hope to determine whether our formula for post-filter Hct provides accurate results when compared to measured values. The information obtained from this study will potentially justify the use of utilizing the formula in future studies.\n\nThe procedure of this study is collecting blood samples from the post-filter lines of patients on CRRT at different time points and different flow rates. This will be considered the \"measured post-filter hematocrit\" which will then be compared to the calculated formula above, using the other values obtained from daily labs (for pre-filter hematocrit) and CRRT machine settings.",[192,26,193],"Continuous Renal Replacement Therapy","Hemofilter Clotting",[195,196,197,198,199],"crrt","continuous renal replacement therapy","hemofilter clotting","post-filter hematocrit","filtration fraction","2025-12-07",{"date":202,"type":35},"2025-12-19",{"date":204,"type":35},"2025-03-15",{"date":206,"type":21},"2026-03-15",{"name":208,"class":82},"Gwyndolyn M. Radford",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":43},"100538938","study-of-the-risk-of-ischaemia-following-the-creation-of-an-arteriovenous-fistula-100538938","NCT06297343","Study of the Risk of Ischaemia Following the Creation of an Arteriovenous Fistula","MODIFVASC","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Stage 5 chronic kidney disease, on dialysis or not on dialysis;\n* Requiring the creation of an arteriovenous fistula;\n* Membership of a social insurance scheme;\n* Patient having been informed and having formulated his\u002Fher oral non-opposition to participate in the research.\n\nExclusion Criteria:\n\n* Contraindication to the proposed surgery ;\n* Reduced life expectancy in the opinion of the investigator;\n* Medical or biological conditions which, in the opinion of the investigator, could influence the interpretation of the results of the study or the safety of the patient;\n* Patient uncooperative with protocol requirements or unable to attend scheduled visits to the centre;\n* Other surgical or medical intervention planned during the study;\n* Pregnant or likely to be pregnant (of childbearing age, without effective contraception) or breastfeeding;\n* Participating in another clinical trial, or in a period of exclusion from another clinical trial;\n* Patient under guardianship or deprived of liberty.",{"count":217,"type":21},544,"The purpose of this study is to identify functional vascular changes and clinical factors correlated with the occurrence of short- or medium-term hand ischaemia after arteriovenous fistula creation.",[26],"2025-11-19",{"date":222,"type":35},"2025-11-24",{"date":224,"type":35},"2025-10-20",{"date":39,"type":21},{"name":227,"class":82},"GCS Ramsay Santé pour l'Enseignement et la Recherche",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":55,"phases":238,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":43},"100563773","phase-2-prevent-cardiac-surgery-associated-aki-trial-100563773","NCT06620523","Prevent Cardiac Surgery Associated AKI Trial","Efficacy of Mitochondrial Directed Therapy in Prevention of Cardiac Surgery Associated AKI Prevent Cardiac Surgery Associated AKI Trial (Prevent CSA-AKI Trial)","Inclusion Criteria:\n\n* Adult 18-70 years of age\n* Undergoing elective CPB (Cardiopulmonary Bypass) surgery\n* Baseline GFR (Glomerular Filtration Rate) ≥45 ml\u002Fmin\n\nExclusion Criteria:\n\n* GFR (Glomerular Filtration Rate) \\\u003C45 ml\u002Fmin\n* Solitary kidney\n* Status post-kidney transplant\n* Pregnant women\n* Allergy to CoQ10\n* Allergy to Glutathione\n* Allergy to Cellulose","70 Years",{"count":237,"type":21},242,[239],"PHASE2","Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.",[26,242,243,244],"Coronary Artery Disease","Surgery","Surgery-Complications",[246,247,248,249,250,251,252,253],"cardiac surgery","critical care medicine","anesthesiology","nephrology","cardiopulmonary bypass","renal failure","aki","supplement","2025-10-03",{"date":256,"type":35},"2025-10-08",{"date":258,"type":35},"2024-07-18",{"date":260,"type":21},"2028-06-17",{"name":262,"class":82},"George Washington University",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":52,"enrollmentInfo":271,"targetDuration":4,"studyType":55,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":43},"100562450","analysis-of-paediatric-treatments-with-multifiltratepro-100562450","NCT06603324","Analysis of Paediatric Treatments With multiFiltratePRO","Efficacy and Safety of Paediatric CVVHD Treatment With MultiFiltratePRO: A Prospective Multicenter Study","ECHOped","Inclusion criteria:\n\nGeneral:\n\n* Paediatric Patients:\n* Informed consent signed and dated by legal representative and investigator\u002F authorized physician.\n* The minors have received the information referred to in Article 63(2) MDR in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children.\n* The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator.\n\nStudy-specific:\n\n* Estimated life expectancy greater than 3 days\n* Children under 18 years\n* Body weight ≥8kg and \\\u003C40kg\n* Patients with clinical indication for CVVHD\n\nExclusion criteria:\n\nGeneral:\n\n* Any conditions which could interfere with the patient's ability to comply with the study\n* Patient or legal representative is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations\n* In case of female patients: pregnancy or lactation period\n* Participation in an interventional clinical study during the preceding 30 days\n* Previous participation in the same study\n\nStudy-specific:\n\n* Hypersensitivity to heparin or known history of heparin induced thrombocytopenia (HIT Type II)\n* Uncontrolled bleeding and coagulation disorders\n* Decision to limit therapeutic interventions\n* Inability to establish the required vascular access",{"count":272,"type":21},43,[57],"This clinical study evaluates the performance of the MultifiltratePro in pediatric mode for Continuous Venovenous Hemodiafiltration (CVVHD) in children. Its primary aim is to assess the efficacy of the MultifiltratePro in paediatric mode, specifically in achieving at least 80% of the prescribed effluent dose within 72 hours. Additionally, the study focuses on the safety of this mode in a paediatric setting, closely monitoring for clinical adverse events, hemodynamic instability, and electrolyte imbalances. Paediatric patients with body weights between 8kg and 40kg will be treated with the MultifiltratePro for a period of up to 10 days, with the treatment duration and approach being tailored to the severity of each patient's condition.",[26,276],"CVVHD",[25,278,279,280,281],"Renal Replacement Therapy","Haemodiafiltration","Contintious kidney replacement therapy","Paediatric","2025-08-27",{"date":284,"type":35},"2025-09-04",{"date":286,"type":21},"2025-10",{"date":288,"type":21},"2026-12",{"name":41,"class":42},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":55,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":314},"100515504","tandem-polyurethane-stents-compared-to-single-silicone-stent-for-malignant-ureteral-obstruction-100515504","NCT05992363","Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction","TSTENT","Inclusion Criteria:\n\n* patient with malignant ureteral obstruction\n\nExclusion Criteria:\n\n* ureteral obstruction of other causes\n* Language comprehension or other limitation in giving informed consent",{"count":298,"type":21},106,[57],"Malignant ureteral obstruction (MUO) is an extrinsic ureteral obstruction caused by malignant diseases. This study aim to compare tandem 6 Fr Percuflex™ stents and single large-caliber 8Fr silicone stent in patients with MUO. The primary endpoint is stent failure rate. The secondary endpoints are patient comfort, quality of life and overall survival.",[302,26,303,304,305],"Hydronephrosis; Obstruction, Ureter","Malignancy","Ureter Obstruction","Ureter Stricture","2025-07-22",{"date":308,"type":35},"2025-07-24",{"date":310,"type":35},"2023-12-20",{"date":39,"type":21},{"name":313,"class":82},"Rabin Medical Center",2,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":322,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":55,"phases":326,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":340},"100520243","phase-4-sglt2-inhibition-in-addition-to-lifestyle-intervention-and-risk-for-complications-in-subtypes-of-patients-with-prediabetes-100520243","NCT06054035","SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes - a Randomized, Placebo Controlled, Multi-center Trial","Inclusion criteria:\n\n1. Male, female or intersexualpatients aged between 35 and 75 years (including)\n2. Prediabetes (defined by one of the following: FG ≥ 100 mg\u002FdL or 2h OGTT glucose ≥ 140 mg\u002FdL)\n3. BMI ≥20 kg\u002Fm2\n4. TSH within normal range\n5. Ability to understand and follow study-related instructions\n6. Negative pregnancy test for premenopausal women (blood)\n7. Patients who are receiving thyroid replacement therapy must be on a stable treatment regimen for at least 3 months prior to the screening visit (V-1)\n8. Patients who are receiving antihypertensive medication such as mineralocorticoid receptor antagonists must be on a stable treatment regimen for at least 6 weeks prior to the screening visit (V-1)\n9. Patients who are treated antihypertensive medication such as ACE inhibitors and AT1receptor antagonists, thiazides as well as loop diuretics must be on stable treatment for at least 2 weeks\n10. Understand and voluntarily sign an informed consent document prior to any study related assessments\u002Fprocedures.\n11. Patients will not be included in the study if, in the opinion of the investigator participation will lead to an unacceptable risk to the subjects' safety or well-being\n\nExclusion Criteria\n\n1. Manifest diabetes mellitus\n2. eGFR (as calculated by the CKD-EPI equation) \\\u003C 60 ml\u002Fmin\u002F1.73 m2\n3. all glucose altering medications (including current therapy with dapagliflozin or empagliflozin or any other SGLT2-Inhibitor)\n4. Symptomatic chronic congestive heart disease\n5. New diuretic or antihypertensive medication or dosing changes within the last 2 weeks, for aldosterone antagonists within the last 6 weeks\n6. known or suspected orthostatic proteinuria\n7. any acute severe or chronic severe illness, including the following: malignant disease ongoing or \\\u003C 5 years ago, unstable cardiovascular disease or procedure within 3 months prior to enrolment or expected to require coronary revascularisation procedure\n8. history of or current therapy for congestive heart failure (NYHA III and IV), pacemaker or aortic stenosis \\> II°\n9. acute pancreatic disease (i.e. elevated lipase 3x ULN)\n10. rapidly progressing renal disease or anuria\n11. known HIV infection or positive HIV test at screening\n12. history of or planned organ transplantation\n13. history or presence of inflammatory bowel disease or other severe gastrointestinal diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis\n14. relevant hepatic disease, including, but not limited to, acute hepatitis, chronic active hepatitis, or severe hepatic insufficiency, including patients with alanine aminotransferase and\u002For aspartate aminotransferase \\> 3 x upper limit of normal and\u002For total bilirubin (TB) \\> 2 mg\u002FdL (\\> 34.2 μmol\u002FL) (patients with TB \\> 2 mg\u002FdL \\[\\> 34.2 μmol\u002FL\\] and documented Gilbert's syndrome will be allowed to participate).\n15. treatment with glucocorticoids\n16. antibiotic treatment within the last 4 weeks\n17. History of ketoacidosis\n18. history of repeated urogenital infection\n19. hemoglobinopathies, haemolytic anaemia, or chronic anaemia (haemoglobin concentration \\\u003C12.0 g\u002FdL)\n20. presence of psychiatric disorder or new intake of antidepressant or antipsychotic agents(start within last 3 months)\n21. Positive Screening for a severe depression (BDI ≥29)\n22. history of hypersensitivity to the study drug or its ingredients\n23. more than 5% weight loss in the last 3 months\n24. Pregnant or breastfeeding women\n25. Subject (male, female or intersexual) is not willing to use highly effective contraceptive methods during treatment and for 14 days (male or female) after the end of treatment (highly effective methods are defined as: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).\n\n    Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success.\n26. Current participation in other interventional clinical trials or treatment with other IMPs within five times the half-life of the drug\n27. Previous therapy with dapagliflozin or other drugs that can potentially lead to overlapping toxicities within five times the half-life of the drug\n28. Patients who do not want to be informed about accidental findings\n29. Any other clinical condition that would jeopardize subjects' safety or well-being while participating in this clinical trial\n30. Patients will not be included in the study if, in the opinion of the investigator, participation leads to an unacceptable risk to their safety and well-being","35 Years","75 Years",{"count":325,"type":21},170,[327],"PHASE4","More than 50% of patients with type 2 diabetes develop micro- and\u002For macrovascular complications during the course of the disease. Additionally, many patients at risk for diabetes develop metabolically driven complications including kidney and heart disease. Thus, it is of utmost importance to improve prevention of T2D and with this complications. Remission of prediabetes, i.e. normalization of hyperglycemia by means of lifestyle intervention is one of the most effective ways to prevent the development of T2D and complications. Novel sub-phenotyping analysis identified clusters of risk for diabetes associated with different complications, opening opportunities to new therapeutic approaches, despite and in addition to lifestyle changes. So far, pharmacological therapy is not indicated for patients with prediabetes. Remission of hyperglycemia associated with prediabetes during lifestyle interventions not only prevents T2D but is also linked with reduced albuminuria and lower microvascular and kidney complications. Thus, reaching normoglycemia (i.e. prediabetes remission) is important for reducing the risk of (pre-)diabetes-associated complications including micro- and even macrovascular disease. In patients with T2D, recent data show that dapagliflozin can improve diabetes remission, and thus, likely complications. However, to date no data have assessed whether or not this is also true in patients with hyperglycemia related to prediabetes which, as outlined above, already causes different complications.\n\nSubphenotyping of patients with newly onset diabetes suggests that for some individuals, it would be too late to start interventions against dagainst complications at the time of diagnosis of type 2 diabetes. Therefore, individuals at elevated risk to develop T2D and complications should receive preventive measures well before the diagnosis of T2D. This study will provide evidence whether such an early intervention contributes to the remission of hyperglycemia related to prediabetes to protect from associated complications such as renal disease. The studied population will comprise individuals who have hyperglycemia in the range of prediabetes and are thus prone to not only develop T2D, but also early nephropathy but in clinical practice do not receive medical treatment due to the early stage of the disease. These subjects will receive Dapagliflozin 10 mg or Placebo for 6 months. The placebo treatment arm reflects current practice. In order guarantee a benefit the patients in the placebo arm will receive a lifestyle intervention.",[330,331,26],"Type2diabetes","PreDiabetes","2025-07-21",{"date":308,"type":35},{"date":335,"type":35},"2023-10-26",{"date":337,"type":21},"2027-09-30",{"name":339,"class":82},"University Hospital Tuebingen",9,{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":314},"100460984","retrospective-analysis-of-performance-and-treatment-data-collected-for-genius-sleddflux-filter-ultraflux-av-600-s-filter--genius-90-concentrates-in-haemodialysis-patients-100460984","NCT05282732","Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients","Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Acute Haemodialysis, Haemodynamically Instable Patients and Chronic Haemodialysis Patients","Genius","Inclusion Criteria:\n\n* All patients with an indication for the extracorporeal blood treatment suffering from renal insufficiency who received all treatments, between January 2019 and December 2019, with the investigational devices have to be included in the study in chronological order.\n* For aHD patients: availability of at least 3 of the 5 primary variables (daily urea, creatinine, potassium, ultrafiltration and effluent volume) for 50 % of the documented treatments.\n* For cHD patients: availability of the ultrafiltration values for all treatments and at least one value for urea and creatinine per week\n\nExclusion Criteria:\n\n* Simultaneous use of another filter\u002Fadsorber for another form of therapy",{"count":350,"type":21},100,"Retrospective analysis of performance and treatment data collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter \\& Genius 90 Concentrates in acute haemodialysis, haemodynamically instable patients and chronic haemodialysis patients\n\n* to analyse performance and treatment data from patients treated with the investigational device\n* to evaluate the filter characteristics for aHD (Acute haemodialysis) patients\n* to evaluate the improvement of kidney function for aHD patients",[26,153,353],"Acute Renal Failure",[168,355,356],"Genius system","Slow extended daily dialysis","2025-06-17",{"date":359,"type":35},"2025-06-22",{"date":361,"type":35},"2022-10-07",{"date":363,"type":21},"2025-12",{"name":41,"class":42},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":323,"enrollmentInfo":372,"targetDuration":4,"studyType":55,"phases":374,"briefSummary":375,"conditions":376,"keywords":379,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":43},"100499824","phase-4-can-dapagliflozin-preserve-structure-and-function-in-transplanted-kidneys-100499824","NCT05788276","Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?","DEAKTransplant","Inclusion Criteria:\n\n* Renal transplant recipients transplanted 6 weeks earlier at Oslo University hospital (OUH) Rikshospitalet.\n* Age 18-75 years.\n* Able to comply with the medical treatment on their own.\n* Calcineurin inhibitor trough concentrations in accordance with individual therapeutic range and standard dose prednisolone and mycophenolate mofetil over the last 2 weeks.\n* Estimated GFR ≥25 mL\u002Fmin\u002F1.73 m2.\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Rejection episodes of the kidney graft prior to randomization.\n* Ongoing infectious disease or intermittent causes affecting renal function, e.g., obstructive lymphocele.\n* Malnutrition.\n* Urosepsis less than 1 year prior to randomization.\n* Participants with a known hypersensitivity to dapagliflozin or any of the excipients of the product.\n* For women only - currently pregnant",{"count":373,"type":21},330,[327],"The goal of this clinical trial is to look at the effect of SGLT2 (Sodium glucose transporter 2) inhibition in patients receiving a kidney-transplant 6 weeks earlier at Oslo University hospital. Rikshospitalet. Investigators will search for answers along three pathways: Can SGLT2 inhibitor 1) preserve glomerular filtration rate (GFR), 2) reduce interstitial fibrosis in the kidney, and 3) favorably improve metabolic risk factors for graft failure such as visceral obesity, glucose intolerance and high blood pressure? The participants (N=330) will be randomized to either dapagliflozin 10 mg or placebo o.d. in a blinded fashion. Researchers will than use kidney transplant biopsies, measured GFR, blood pressure sampling, glucose tolerance test (OGTT), dual-energy X-ray absorptiometry (DXA scan) and estimated GFR from the two groups in comparison, to evaluate the effect treatment. The participants will be followed for a total of 3 years.",[377,378,26],"Kidney Transplant; Complications","Kidney Transplant Failure",[380,381,382,383],"Kidney","Transplantation","SGLT2","Renal function","2025-03-26",{"date":386,"type":35},"2025-04-01",{"date":388,"type":35},"2023-05-02",{"date":390,"type":21},"2028-06",{"name":392,"class":82},"Oslo University Hospital",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":55,"phases":402,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":4},"100536846","dial-bicarb-trial-effects-of-a-lower-vs-higher-concentration-of-dialysate-bicarbonate-100536846","NCT06270134","Dial-Bicarb Trial: Effects of a Lower vs. Higher Concentration of Dialysate Bicarbonate","Dial-Bicarb Trial: Effects of a Lower vs. Higher Concentration of Dialysate Bicarbonate for People Receiving Maintenance Hemodialysis","Inclusion Criteria:\n\n* The dialysis centre director and all nephrologists who provide care in the centre agree to trial participation.\n* Adult patients 18 years of age and older, with a health card number, enter the trial after they receive hemodialysis for at least 90 days (about 3 months) so that patients with acute kidney injury who recover kidney function are excluded.\n\nExclusion Criteria:\n\n\\- Participating centres are instructed that patients on in-centre nocturnal hemodialysis or in-centre frequent (greater than four times weekly) hemodialysis are not in the trial (and do not receive the allocated intervention), since these patients usually receive dialysate bicarbonate concentrations ≤32mmol\u002FL as standard care (based on Ontario registry data, these modalities represent \\\u003C5% of the hemodialysis patient population).",{"count":401,"type":21},14000,[57],"This is a pragmatic, two-arm, parallel-group, open-label, individual-randomized, superiority trial that will be conducted in hemodialysis units across Ontario. Patients at each dialysis unit will be randomly allocated into one of two study arms in a 1:1 ratio to receive a dialysate bicarbonate concentration of either 32 or 38 mmol\u002FL. The intervention will be embedded into routine care and delivered by hemodialysis unit personnel.",[26,168],[406,251,407,408,409],"bicarbonate","kidney","pragmatic trial","maintenance hemodialysis","2025-03-17",{"date":412,"type":35},"2025-03-20",{"date":414,"type":21},"2025-04",{"date":416,"type":21},"2029-04",{"name":418,"class":82},"McMaster University",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":55,"phases":427,"briefSummary":429,"conditions":430,"keywords":431,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":444},"100531759","phase-1-inflammation-reduction-to-prevent-cardiovascular-injury-in-renal-disease-repair-100531759","NCT06203977","Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)","Inclusion Criteria:\n\n1. One of either:\n\n   1.2 Estimated GFR using CKD-EPI 2021 equation of ≤30 ml\u002Fmin\u002F1.73m2 on at least two occasions separated by at least 2 months and do not yet require dialysis and are not expected by their treating nephrologist to require dialysis in the next 6 months (REPAIR CKD cohort), or 1.3 receiving chronic maintenance dialysis 2 or more times per week for the previous 90 days (REPAIR Dialysis cohort);\n2. Age ≥18 years\n3. Provide informed consent to participate.\n\nExclusion Criteria:\n\n1. Currently treated with and cannot withdraw colchicine due to medical necessity; or\n2. Known allergy\u002Fsensitivity to colchicine; or\n3. Prior self-reported intolerance to colchicine at a dose of 0.6 mg daily or lower; or\n4. Currently pregnant or planning to become pregnant or breastfeed during the study; or\n5. Of childbearing potential AND do not have a negative pregnancy test OR do not agree to use two forms of contraception for the duration of the study; or\n6. Anticipated living donor renal transplant within the next 6 months; or\n7. Using a strong inhibitor of p-glycoprotein or strong inhibitor of CYP3A4 in the last 14 days; or\n8. B12 deficiency not managed with intramuscular supplementation; or\n9. Uncontrolled chronic diarrhea; or\n10. Cirrhosis, or chronic active hepatitis; or\n11. Pre-existent neuromuscular disease or persistent serum CK level \\> 3 times the upper limit of normal as measured within the past 60 days and determined to be non-transient through repeat testing; or\n12. Patient with any of the following within the past 60 days:\n\n    * white blood cell count \\\u003C 3.0 X 109\u002FL; or\n    * platelet count \\\u003C110 X 109\u002FL; or\n    * ALT or AST \\> 3 times the upper limit of normal (ULN); or\n    * total bilirubin \\> 2 times ULN and not due to Gilbert syndrome.\n13. Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.",{"count":426,"type":21},200,[428],"PHASE1","Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.",[152,26],[432,433,434],"Tolerance","Colchicine Resistance","Hematologic markers","2025-03-10",{"date":437,"type":35},"2025-03-12",{"date":439,"type":35},"2024-11-15",{"date":441,"type":21},"2026-05-31",{"name":443,"class":82},"Hamilton Health Sciences Corporation",3,{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":452,"targetDuration":454,"studyType":22,"phases":4,"briefSummary":455,"conditions":456,"keywords":464,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":43},"100500545","comparing-the-diagnostic-sensitivity-and-specificity-of-pleural-fluid-n-terminal-pro-b-type-natriuretic-peptide-nt-probnp-and-other-biochemical-gradient-criteria-in-distinguishing-heart-failure-and-non-heart-failure-related-pleural-effusions-centre-study-100500545","NCT05797649","Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)","Comparing N-terminal-proB-type Natriuretic Peptide with Other Diagnostic Criteria in Discriminating Heart Failure-associated from Non-heart Failure-associated Pleural Effusions","Inclusion Criteria:\n\n* Patients hospitalized for heart failure and pleural effusion\n* Pleural tapping indicated for pleural fluid analysis.\n* Aged 18 years old or above\n\nExclusion Criteria:\n\n* History of intrapleural therapy (including talc and fibrinolytic) in the ipsilateral pleural space.\n* History of surgical decortication or pleurodesis in the ipsilateral pleural space.\n* Ipsilateral thoracic or cardiac surgery in the past 3 months.\n* Failure to obtain informed consent due to the patient's refusal or cognitive impairment.",{"count":453,"type":21},120,"24 Months","To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).",[457,458,459,460,461,26,462,463],"Pleural Effusion","Heart Failure","Malignant Neoplasm","Fluid Overload","Hypoalbuminemia","Cirrhosis","Infections",[465,466,467,468,469,470,471,472],"pleural fluid","heart failure","malignancy","cancer","echocardiography","infection","tuberculosis","respiratory medicine","2024-11-11",{"date":475,"type":35},"2024-11-13",{"date":477,"type":35},"2023-07-01",{"date":479,"type":21},"2025-11-30",{"name":481,"class":82},"Chinese University of Hong Kong",{"id":483,"slug":484,"hasResults":11,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":55,"phases":491,"briefSummary":492,"conditions":493,"keywords":494,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":43},"100346197","exercise-in-patients-with-end-stage-kidney-disease-100346197","NCT03787589","Exercise in Patients With End Stage Kidney Disease","A Simple Exercise Program for Patients With End Stage Kidney Disease to Improve Strength and Quality of Life: A Feasibility Study","Inclusion Criteria:\n\n1. All ambulatory adult patients with end stage kidney disease\n2. Treatment with peritoneal dialysis or hemodialysis for greater than six months\n3. Able to understand English or French\n4. Abuse to use Nordic Walking poles\n5. Able and willing to provide informed consent\n\nExclusion Criteria:\n\n1. Any absolute contraindication to exercise \\[unstable angina, uncontrolled hypertension (systolic or diastolic blood pressure greater than 180 mmHg (millimeters of mercury) or greater than 110 mmHg, respectively), deemed not suitable for exercise by the treating physician\\]\n2. Baseline step count greater than 8000 steps a day\n3. Planned living donor kidney transplant\n4. Potential for recovery of renal function\n5. Patients who feel unsafe using Nordic walking poles in place of their mobility aid\n6. Participation in another interventional trial that may affect the results of this study",{"count":490,"type":21},90,[57],"This study will be conducted over a 3 year time period. This is a trial of an exercise intervention vs. standard of care in patients receiving chronic dialysis. The specific aims will be to determine feasibility of patient recruitment, adherence to the exercise program, and efficacy of the intervention on patient important outcomes.\n\nThe exercise intervention will be delivered to randomized participants for 12 months, and consist of the prescribed use of Nordic Walking poles, online resources for exercise in the home, regular use of a pedometer to monitor progress, and regular verbal encouragement to exercise (monthly) by dialysis unit staff. Both groups will receive the same standard of care co-interventions including individualized dialysis prescriptions and health-care interactions according to practices at their centre.",[26],[26,168,495,496],"Peritoneal Dialysis","Exercise","2024-06-24",{"date":499,"type":35},"2024-06-26",{"date":501,"type":35},"2019-04-15",{"date":503,"type":21},"2025-09-15",{"name":505,"class":82},"Ottawa Hospital Research Institute",{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":513,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":55,"phases":516,"briefSummary":517,"conditions":518,"keywords":534,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":4},"100354774","phase-1-safety-and-clinical-outcomes-with-amniotic-and-umbilical-cord-tissue-therapy-for-numerous-medical-conditions-100354774","NCT03899298","Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions","Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions","Inclusion Criteria:\n\n1. Age 18 and over.\n2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.\n3. Competent to understand the study protocol and provide voluntary informed consent.\n4. Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back\u002FNeck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.\n\nExclusion Criteria:\n\n1. Active Cancer\n2. Pregnancy, Lactating\n3. Severe Clotting disorder\n4. Myocardial Infarction less than six months ago.",true,{"count":515,"type":21},5000,[428],"To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.",[519,520,521,522,523,26,160,524,525,526,527,528,529,530,531,532,533],"Orthopedic Disorder","Neurologic Disorder","Urologic Diseases","Erectile Dysfunction","Autoimmune Diseases","Kidney Diseases","Cardiac Event","Cardiomyopathies","CHF","Pulmonary Disease","COPD","Alzheimer Disease","Stroke","Neuropathy;Peripheral","Arthritis",[535,536,537,538,539,540,541,542],"stem cell therapy","umbilical stem cells","amniotic stem cells","stem cells","regenerative medicine","r3 stem cell","perinatal tissue","placenta stem cell","2019-08-20",{"date":545,"type":35},"2019-08-22",{"date":547,"type":21},"2019-09-01",{"date":549,"type":21},"2029-03-20",{"name":551,"class":42},"R3 Stem Cell"]